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Beyond Evidence-Based Medicine
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exist but are not widely disseminated. For example, the Cleveland Clinic, Texas Children’s Hospital, and other institutions have
had every physician undergo formal training in communication
skills.
The next step is measuring processes and outcomes, which requires agreement on metrics or appropriate surrogates. The research
underpinning EBM suggests that
“soft” outcomes are often the important ones and can be measured
rigorously even when they’re variable. If trust is the foundation
on which clinician–patient relationships are built, for example,
we have work to do in measuring
it. Because improvement is important, measurement should be done
in real time so that clinicians can
respond nimbly, and the outcomes
from multiple perspectives (such
as patients, families, and other
clinicians) should be captured.
The third step is enabling interpersonal medicine, which requires
developing matchmaking protocols that predict stronger relationships, so we can pair clinicians
and patients for success, creating
environments that reduce anxiety
and foster interaction. It also re-

quires instituting service standards, best practices, and tools
that encourage productive dialogue. For example, Dell Medical
School’s clinics have no waiting
rooms. Patients are shown directly to a room that is designed primarily to accommodate conversation among the patient, family
members, and the clinicians who
will visit them. No exam table is
in sight; a chair converts to an
exam table when necessary.
The final step is creating incentives for interpersonal medicine, both financial and nonfinancial. This step is fraught with
political hazards but could accelerate improvement. It requires rating and benchmarking clinicians
on the basis of outcomes, relationships, and understanding and
moving beyond productivity as a
primary value indicator. It requires asking patients and caregivers to contribute to those ratings, and transparency in the form
of their internal and external publication. Ultimately, transparency
is the most effective way to celebrate and recognize humanistic
skill in parity with scientific accomplishments.
None of these elements are un-

attainable: some solutions have
already been proposed and (inconsistently) instituted, if not in medicine, then in adjacent or analogous
fields. This effort is not about addressing lack of knowledge, but
about building systemic capability
at a scale that mirrors our scientific effort. We can pursue an empathetic version of medicine that
embraces emotion and appreciates
behavior if we value human nature as much as human biology.
Disclosure forms provided by the authors
are available at NEJM.org.
From the Design Institute for Health, Dell
Medical School, Austin, TX (S.C.); and
Press Ganey and Harvard Medical School
— both in Boston (T.H.L.).
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early 75 million U.S. residents have health insurance
coverage through Medicaid. Benefits and program designs vary
from state to state. One source of
state-based variation is Section
1115 projects, which are defined
as “experimental, pilot, or demonstration” programs that are “likely to assist in promoting the objectives” of the Medicaid statute.
States seeking to implement experimental policies in their Med-

icaid programs must apply to the
Centers for Medicare and Medicaid Services (CMS) for a Section
1115 waiver, which lifts certain
federal regulations for 5 years.
Thirty-seven states had active Section 1115 waivers as of October
31, 2018 (see map),1 and more
than one third of Medicaid
spending goes toward Section
1115 programming.2
Section 1115 waivers are becoming more consequential as
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CMS considers allowing states to
implement policies that were disfavored by prior administrations.
Foremost among these policies are
community engagement requirements, which mandate that nondisabled, nonpregnant adults meet
monthly quotas for time engaged
in work, volunteer activities, or
school to maintain their Medicaid coverage.3 Other proposed
waiver terms include beneficiary
premiums with coverage lockouts
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for people who do not pay, premium surcharges for tobacco use,
elimination of retroactive eligibility, lifetime limits on coverage
(which were rejected by CMS this
year), drug screening and asset
testing for beneficiaries, expansion
of substance use treatment, elimination of nonemergency medical
transportation services, and incentives or benefits tied to engagement in healthy behaviors.1
Many commentators have considered the legality of proposed
waiver terms.4 We believe that
another important consideration
is the legal, ethical, and practical
imperative of conducting rigorous
evaluations when CMS grants Section 1115 waivers for untested
policies. Many proposed waiver
terms have never previously been
implemented in Medicaid programs, and their effects on beneficiaries’ health are unknown.
Every Section 1115 project is an
experiment, and robust evaluations
are essential in order for such experiments to yield useful lessons
for Medicaid program design.
Although states have long studied their Section 1115 projects, in
recent years federal requirements
have changed the scope of those
evaluations. States are now required to evaluate their demonstrations, and CMS mandates the
use of independent evaluators.2
Evaluators work with states to
submit protocols to CMS, and research is jointly funded by states
and CMS. The Affordable Care
Act added to these requirements,
mandating public posting of evaluation hypotheses, designs, timelines, and results. States applying
for waiver renewals submit evaluation reports, which must include
data on outcomes related to insurance coverage, access to care,
quality of care, and beneficiary
satisfaction.
Many evaluations of Section
1986

1115 projects, however, have had
little impact on policy. The Government Accountability Office has
noted striking methodologic deficiencies in prior evaluations —
including lack of comparison
groups, insufficient sample sizes,
failure to test key hypotheses, and
selective reporting of outcomes
— in part because of insufficient
funding for this research.2 Reports have been delayed for years
after waiver cycles, which limits
their usefulness to CMS, as well
as to other states considering similar projects. CMS has revised expectations regarding evaluation
independence and methods,2 but
often past Section 1115 waivers
have taught policymakers little
about what works.
New evaluations should break
from these precedents. In states
where waivers have already been
approved, we believe that evaluators should identify and test
states’ health promotion goals.
And when new waiver policies
are proposed, CMS should urge
states to incorporate randomized,
controlled trials into their evaluations. Although health policy
trials are rare, past examples —
such as the RAND cost-sharing
study and the Oregon Health Insurance Experiment, which evaluated a Section 1115 project —
have contributed substantially to
public understanding of the effectiveness of the policy innovations
tested.5 Section 1115 projects already expose Medicaid beneficiaries to risks and benefits in the
name of experimentalism, and
they spend public funds with the
promise of advancing Medicaid’s
goals over the long term. Using
rigorous study designs to evaluate these projects will ensure that
they yield useful lessons.
Designs used in prior evaluations of Section 1115 projects,
such as before-and-after compari-
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sons and difference-in-differences
analyses incorporating data from
multiple states, have had many
limitations. Medicaid and the individual insurance market both
undergo frequent legislative and
regulatory changes that confound
before-and-after comparisons. As
Section 1115 waivers proliferate,
there is also no guarantee of having a stable, appropriate comparison group. For example, Kentucky
was the first state to receive approval for a Section 1115 waiver
permitting community engagement requirements, although the
waiver is currently blocked by a
federal court decision. Neighboring states that expanded Medicaid
— including Indiana, Ohio, Illinois, and West Virginia — could
theoretically serve as controls in
an evaluation of Kentucky’s demonstration if it moves forward.
But Indiana recently received approval for a similar waiver, and
Ohio’s waiver application is pending, making use of these states
as comparators problematic. States
that incorporate randomization
into the rollout of their Section
1115 projects will have rigorous
evaluations regardless of other
states’ choices.
Incorporating randomization
into Section 1115 projects may
prompt several concerns. One is
related to administrative capacity:
states using a randomized trial
to evaluate a new program must
implement a different version of
Medicaid for each study arm. But
in fact states already provide different benefits to different statutory classes of beneficiaries. For
example, recent Section 1115 waivers focus on people covered under
Medicaid expansion but exempt
other beneficiaries, such as those
who are pregnant, elderly, or medically frail. States implementing
these waivers already have the necessary infrastructure to facilitate
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exemptions. A randomized, controlled trial would use this existing
capacity and extend exemptions to
a randomly selected control group.
A second concern involves the
ethical issue of equipoise: is there
sufficient uncertainty regarding
how the waiver will affect beneficiaries as compared with the
existing program? Under federal
regulations, research that is subject to approval by a federal
agency head, and that is “designed
to study, evaluate, improve, or
otherwise examine public benefit
. . . programs,” is exempt from
the requirements for review by an
institutional review board. When
CMS reviews a Section 1115 waiver
application, the Medicaid statute
asks the agency to consider the
potential benefits and to approve
only waivers that are likely to advance program goals. Once CMS

grants approval for a new waiver
policy, all eligible beneficiaries in
the state are exposed to the terms
of the waiver. This approach has
no ethical advantage over randomization; instead, it exposes a larger number of beneficiaries to the
risks and benefits of an untested
policy and it strips waivers of
their intended purpose — testing
the effects of new Medicaid terms.
A third concern relates to the
many methodologic choices involved in designing randomized,
controlled trials. States and their
evaluators must decide whether
to study the effects of a waiver as
a whole or individual waiver terms,
how to define units of randomization (e.g., counties, households,
or individual beneficiaries), how to
address participant consent and
compensation for new data collection, and how to conduct analy-
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ses. These choices may be daunting, but they are surmountable
with evaluation expertise.5 They
are also less formidable than the
analytic challenges involved in
identifying appropriate control
groups for nonrandomized evaluations. If states establish robust
study designs at the outset, evaluations will have payoffs for the
duration of Section 1115 demonstrations and for other states considering similar waiver terms.
States and CMS can also
strengthen evaluation designs by
using mixed methods to assess untested policies. Quantitative analyses should include prespecified
hypotheses and sample sizes that
provide enough statistical power
for two-tailed tests, whereas qualitative methods can help researchers understand beneficiaries’ and
providers’ experiences with new
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programs. Combining these insights can help explain key findings, illuminate unanticipated
effects, and clarify self-reported
outcomes such as quality of life.
Many new Section 1115 waiver
policies are controversial, which
raises the stakes for postapproval
evaluations. Waiver policies are
also diffusing rapidly; as states
exchange ideas, their evaluations
should establish a knowledge base
for Medicaid policy choices. Section 1115 waivers rely on experimentalism, and the model of
states as laboratories can best
fulfill this commitment by producing meaningful evidence of the
effects of experimental programs.
For untested waiver policies, we
believe that CMS and states

Doctor Sahib

should take “experimentalism”
literally and harness the rigor of
randomized, controlled trials.
Disclosure forms provided by the authors
are available at NEJM.org.
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Doctor Sahib
Saurabh Jha, M.B., B.S.

M

any of my father’s patients,
Pakistanis who migrated to
Britain to save dying manufacturing industries (which were starved
for laborers), did not take their
medications. His most memorable
patient was Mr. Khan, a goodnatured Pathan (Pashtun) who
hailed from the border zone between Pakistan and Afghanistan.
Mr. Khan feared no one except
Allah, doctors, and his wife. That
he feared my father struck me
as endearingly comical, since he
towered nearly a foot above him.
Mr. Khan, with hypertension,
diabetes, and a lipid profile suggestive of a silent uprising — a
sort of Metabolic Spring against
a tyranny of red meat — would
play hooky from his medications.
On one occasion, my father recalls, Mr. Khan’s wife accompanied him to a consultation. She
begged my father to reproach her
husband for failing to bring his
medications on a recent visit to

1988

Pakistan. Mr. Khan said, cheekily,
that the weight limit for checked
baggage had been exceeded, so
he’d had to leave the medications
behind.
Neither Mr. Khan nor his wife
spoke a word of English, but my
father understood them not just
because he was fluent in Urdu: as
a migrant himself, he understood
that most people from the Indian
subcontinent — Muslims, Hindus,
and Sikhs alike — don’t see doctors unless they’re ill and don’t
take their medications unless they
have symptoms. Mr. Khan’s blood
pressure was climbing perilously
high, and my father’s challenge
was getting him to take his medication. So my father indulged in
a subcontinent variant of shared
decision making, a variant not
taught in medical school.
My father: “Khan Sahib, aapko
dawaii lai nee paregi.” (You must take
your medication.)
Mr. Khan: “Doctor Sahib, agar
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nahi, to kya hoga?” (What will happen if I don’t?)
My father: “Tab aapka haath or
pare nahi chalega.” (You will become
paralyzed.)
Mr. Khan: “Tab kya hoga, doctor
sahib?” (What will happen next?)
My father: “Tab aapka beta aapka
zyadaad lega aura aapko ghar se nikaal
dega.” (Then your son will take
your property and throw you out
of the house.)
Mr. Khan (laughing): “Tab to
mujhe dawaii lainee paregi.” (Then I
must take my medication.)
My father never asked Mr. Khan
what his values and preferences
were — he knew such an approach
would be pointless, because Mr.
Khan saw the job of the doctor as
telling him what to do, not asking
what outcomes he wanted. If my
father used decision aids to explain
the trade-offs between various
anticoagulants in order to arrive at
a shared decision, Mr. Khan would
probably have been befuddled.
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